PedAM
Pediatric Disease Annotations & Medicines
| Disease | pleural effusion disorder |
| Phenotype | C0007131|nsclc |
| Sentences | 13 |
| PubMedID- 23159850 | For example, cells derived from biopsies or from malignant pleural effusions of patients with nsclc give rise efficiently to propagating tumor spheroids in culture,8 which are, again, enriched in csc markers.8,9 in conclusion, in vitro cultures of tumor spheroids from stabilized cell lines and from fresh tumor specimens may therefore be considered a useful in vitro model to screen for new agents capable of co-targeting both cscs or emt malignant features of cancer cells. |
| PubMedID- 20207133 | Patients and methods: twelve of 15 nsclc patients with malignant pleural effusions were treated with paclitaxel liposome and three were treated with free paclitaxel. |
| PubMedID- 25554695 | However, the proteome of pleural effusion in nsclc patients is not well understood, nor is the variability in protein composition between malignant and benign pleural effusions. |
| PubMedID- 20819493 | Objective: to compare the therapeutic effects of pleural perfusion of ndp and cddp in non-small cell lung cancer (nsclc) patients with malignant pleural effusion, their quality of life and toxic side effects. |
| PubMedID- 26134225 | Introduction: a subset of non-small-cell lung cancer (nsclc) patients with malignant pleural effusion and/or malignant pleural nodules is now classified as stage iv and is generally considered a contraindication to surgery. |
| PubMedID- 23925664 | Vascular endothelial growth factor (vegf) is involved in non-small cell lung cancer (nsclc) with malignant pleural effusion (mpe), but little is known regarding the efficacy of bevacizumab (bev) with carboplatin-paclitaxel (cp) for nsclc with mpe. |
| PubMedID- 24523811 | The enrolled chemotherapy-naïve patients had either stage iiib nsclc with pleural effusion or stage iv nsclc. |
| PubMedID- 23726527 | We studied 37 nsclc patients with malignant pleural effusion. |
| PubMedID- 25818753 | However, the impact on the survival of nsclc patients with malignant pleural effusion and/or pleural nodules still remains uncertain given the small number of patients enrolled in the study. |
| PubMedID- 23033932 | Key eligibility criteria included: age ≥ 70, diagnosis of advanced nsclc (stage iiib with pleural effusion or iv[17]); measurable disease according to modified recist criteria version 1.0[18]; eastern cooperative oncology group performance status (ecog-ps) 0 to 2; adequate organ function. |
| PubMedID- 26338423 | The presence of pleural effusion in patients with nsclc usually indicates advanced disease and portends a grave prognosis5. |
| PubMedID- 25620478 | Conclusions: ccl18 is present at a high level in mpe and serum of nsclc patients complicated with pleural effusion and a moderate positive correlation exists between ccl18 levels in the two fluids. |
| PubMedID- 22457603 | Rr was 35% vs 15% (p < 0.001), pfs was 6.2 m vs 4.5 m (hr 0.66; 95% ci: 0.57–0.77; p < 0.001) and os was 12.3 m vs 10.3 m (hr 0.79; 95% ci: 0.67–0.92; p = 0.003).6 patients analyzed in this study had nonsquamous type nsclc stage iiib with pleural effusion, stage iv or recurrent disease, without previous administration of chemotherapy. |
Page: 1